MX362914B - Composición para tratar la diabetes que comprende un conjugado de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada. - Google Patents

Composición para tratar la diabetes que comprende un conjugado de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada.

Info

Publication number
MX362914B
MX362914B MX2013014029A MX2013014029A MX362914B MX 362914 B MX362914 B MX 362914B MX 2013014029 A MX2013014029 A MX 2013014029A MX 2013014029 A MX2013014029 A MX 2013014029A MX 362914 B MX362914 B MX 362914B
Authority
MX
Mexico
Prior art keywords
long
acting
conjugate
insulinotropic peptide
insulin
Prior art date
Application number
MX2013014029A
Other languages
English (en)
Other versions
MX2013014029A (es
Inventor
Chang Ki Lim
Se Chang Kwon
Young Jin Park
Young Eun Woo
Myung Hyun Jang
Young Kyung Park
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of MX2013014029A publication Critical patent/MX2013014029A/es
Publication of MX362914B publication Critical patent/MX362914B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica para reducir niveles de glucosa en sangre, caracterizada porque comprende un conjugado de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada, y presentando un efecto hipoglucémico incrementado comparado con un conjugado de insulina de acción prolongado solo o un conjugado de péptido insulinotrópico de acción prolongada solo; en la que cada uno del conjugado de insulina de acción prolongada y el conjugado de péptido insulinotrópico de acción prolongada se prepara mediante la unión de insulina o péptido insulinotrópico con una región Fc de inmunoglobulina a través de un enlazador no peptidílico seleccionado del grupo constituido por polietilenglicol, polipropilenglicol, copolímero de etilenglicol-propilenglicol, poliol polioxietilado, poli(alcohol vinílico), polisacárido, dextrano, poliviniletiléter, un polímero biodegradable, un polímero lipídico, quitina, ácido hialurónico y una combinación de los m ismos,; y donde el péptido insulinotrópico se selecciona del grupo que consiste en exedina-4 nativa, un derivado de exedina-4 preparado por deleción del grupo amino N-terminal, un derivado de exedina-4preparado por sustitución del grupo amino N-terminal con un grupo hidroxilo, un derivado de exedina 4 preparado por modificación del grupo amino N-terminal con un grupo dimetilo, y un derivado de exedina-4 preparado por elección del carbono-a del primer aminoácido de exedina-4(histidina).
MX2013014029A 2011-06-02 2012-06-01 Composición para tratar la diabetes que comprende un conjugado de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada. MX362914B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110053488 2011-06-02
PCT/KR2012/004367 WO2012165915A2 (en) 2011-06-02 2012-06-01 Composition for treating diabetes comprising long-acting insulin conjugate and long-acting insulinotropic peptide conjugate

Publications (2)

Publication Number Publication Date
MX2013014029A MX2013014029A (es) 2014-04-16
MX362914B true MX362914B (es) 2019-02-26

Family

ID=47260121

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013014029A MX362914B (es) 2011-06-02 2012-06-01 Composición para tratar la diabetes que comprende un conjugado de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada.
MX2018006844A MX2018006844A (es) 2011-06-02 2013-11-28 Composicion para tratar la diabetes que comprende un conjugado de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018006844A MX2018006844A (es) 2011-06-02 2013-11-28 Composicion para tratar la diabetes que comprende un conjugado de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada.

Country Status (21)

Country Link
US (2) US10251957B2 (es)
EP (1) EP2717918B1 (es)
JP (2) JP6320293B2 (es)
KR (1) KR101424550B1 (es)
CN (2) CN109999180A (es)
AR (1) AR086660A1 (es)
AU (2) AU2012263098B2 (es)
BR (2) BR112013030977A2 (es)
CA (1) CA2837856C (es)
CL (1) CL2013003454A1 (es)
ES (1) ES2974001T3 (es)
IL (1) IL229726A (es)
MX (2) MX362914B (es)
MY (1) MY187652A (es)
PE (2) PE20140795A1 (es)
RU (1) RU2606840C2 (es)
SG (1) SG195193A1 (es)
TW (1) TWI560198B (es)
UA (1) UA113626C2 (es)
WO (1) WO2012165915A2 (es)
ZA (1) ZA201308811B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) * 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
WO2014096148A1 (en) 2012-12-21 2014-06-26 Sanofi Functionalized exendin-4 derivatives
KR20140088837A (ko) * 2013-01-03 2014-07-11 한미약품 주식회사 Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
CA2901873C (en) * 2013-02-26 2022-05-03 Hanmi Pharm. Co., Ltd. Novel insulin analog and use thereof
WO2014133327A1 (ko) * 2013-02-26 2014-09-04 한미약품 주식회사 인슐린 위치 특이적 결합체
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
AR096891A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
AR096890A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
BR112016016578A2 (pt) 2014-01-20 2017-10-03 Hanmi Pharm Ind Co Ltd Insulina de ação prolongada e uso daanálogo de insulina, polinucleotídeo, vetor de expressão, transformante, insulina de ação prolongada bem como seu método de preparação e formulação da mesma, conjugado, e uso do mesmo mesma
SG10202107752PA (en) * 2014-03-31 2021-09-29 Hanmi Pharmaceutical Co Ltd Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) * 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
KR20150140177A (ko) 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
US9932381B2 (en) * 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
WO2016011133A1 (en) * 2014-07-15 2016-01-21 The Regents Of The University Of California A peptide therapy to counteract insulin resistance and type 2 diabetes
TWI772252B (zh) * 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
US20160151511A1 (en) 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
WO2016172479A1 (en) * 2015-04-22 2016-10-27 Cedars-Sinai Medical Center Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
JP6712323B2 (ja) * 2015-12-31 2020-06-17 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体
US20190175744A1 (en) * 2016-03-18 2019-06-13 Merck Sharp & Dohme Corp. Insulin-incretin conjugates
CA3037844A1 (en) 2016-09-23 2018-03-29 Hanmi Pharm. Co., Ltd. Insulin analogs with reduced affinity to insulin receptor and use thereof
WO2018057977A1 (en) * 2016-09-23 2018-03-29 Delpor, Inc. Stable compositions for incretin mimetic compounds
AU2018215840A1 (en) * 2017-02-03 2019-08-01 Hanmi Pharm. Co., Ltd. Long-Acting Conjugate Of A Physiologically Active Material And Use Thereof
KR102629006B1 (ko) 2017-03-23 2024-01-25 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
WO2019066603A1 (ko) * 2017-09-29 2019-04-04 한미약품 주식회사 효력이 향상된 지속성 단백질 결합체
EP3781147A4 (en) * 2018-04-16 2022-04-20 University of Utah Research Foundation GLUCOSE-SENSITIVE INSULIN
KR102646845B1 (ko) * 2018-08-08 2024-03-14 주식회사 대웅제약 클로스트리파인을 이용한 지속형 인슐린 아날로그 복합체의 활성형 제조방법
KR102666154B1 (ko) * 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
NZ784956A (en) * 2019-07-18 2023-01-27 Hanmi Pharm Ind Co Ltd Novel method for preparing long-acting drug conjugate through preparation of intermediate
WO2021142733A1 (en) * 2020-01-16 2021-07-22 Shanghai Benemae Pharmaceutical Corporation Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
KR20010041238A (ko) * 1998-02-23 2001-05-15 뉴로크린 바이오사이언시즈 인코퍼레이티드 인슐린의 펩티드 동족체를 사용하는 당뇨병의 치료 방법
JP2005508895A (ja) * 2001-08-28 2005-04-07 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１および基礎インスリンの予備混合物
CA2463803A1 (en) * 2001-10-19 2003-05-01 Eli Lilly And Company Biphasic mixtures of glp-1 and insulin
JP2006514990A (ja) * 2002-12-27 2006-05-18 ディオベックス， インコーポレイテッド インスリン誘発性低血糖の予防および制御のための組成物および方法
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
KR101135244B1 (ko) * 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
PT2239273E (pt) * 2003-11-13 2013-12-10 Hanmi Science Co Ltd Uma composição farmacêutica que compreende um fragmento fc de imunoglobulina como um portador
JP2008513384A (ja) 2004-09-17 2008-05-01 ノボ ノルディスク アクティーゼルスカブ インスリンおよびインスリン分泌性ペプチドを含有する医薬組成物
KR100754667B1 (ko) * 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
US20070054851A1 (en) 2005-05-27 2007-03-08 Junyu Lin Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
US8759290B2 (en) * 2005-10-18 2014-06-24 Biocon Limited Oral glucagon-like peptide conjugates for metabolic diseases
CA2632779A1 (en) 2005-12-08 2007-06-14 Pfizer Inc. Method for demethylating the 3'-dimethylamino group of erythromycin compounds
KR20080001479A (ko) 2006-06-29 2008-01-03 주식회사 하이닉스반도체 포토 마스크의 제조 방법 및 이의 레지스트 반응 생성물제거 장치
EP2076242B8 (en) * 2006-07-27 2013-02-20 Nektar Therapeutics Aerosolizable formulation comprising insulin for pulmonary delivery
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
DK2597103T3 (en) * 2007-11-16 2017-02-13 Novo Nordisk As Stable pharmaceutical compositions comprising liraglutide and degludec
WO2009087082A2 (de) * 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
CN102007143B (zh) * 2008-01-09 2015-08-26 塞诺菲-安万特德国有限公司 具有超延迟时效特征的新型胰岛素衍生物
EP2254559B1 (en) * 2008-02-08 2018-10-10 Foresee Pharmaceuticals Co., Ltd. Composition for sustained release delivery of proteins or peptides
EP2259802A1 (en) 2008-03-31 2010-12-15 Glaxo Group Limited Drug fusions and conjugates
EP2676673B1 (en) * 2008-06-17 2016-11-16 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
NZ590358A (en) 2008-07-23 2012-04-27 Hanmi Holdings Co Ltd A polypeptide complex comprising non-peptidyl polymer having three functional ends
JP2012505637A (ja) 2008-10-15 2012-03-08 アンジオケム，インコーポレーテッド Ｇｌｐ−１アゴニストのコンジュゲート及びその使用
CN102256618A (zh) * 2008-10-17 2011-11-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
KR101035811B1 (ko) 2008-10-28 2011-05-20 현대제철 주식회사 프레스 경화 공정용 강판 이송 장치
JP2010118268A (ja) 2008-11-13 2010-05-27 Kyocera Elco Corp コネクタ
EA200900123A1 (ru) 2008-11-13 2010-06-30 Государственное Научное Учреждение "Физико-Технический Институт Национальной Академии Наук Беларуси" Способ изготовления осесимметричных деталей с поверхностными слоями
EP2376520B1 (en) 2008-12-19 2014-02-12 Indiana University Research&Technology Corporation Insulin analogs
US20120094894A1 (en) 2009-02-13 2012-04-19 Boehringer Ingelheim International Gmbh Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
MA33046B1 (fr) 2009-02-13 2012-02-01 Boehringer Ingelheim Int Composition pharmaceutique contenant un inhibiteur sglt-2, un inhibiteur dpp- iv et facultativemenet un autre agent antidiabetique et ses utilisations
KR101036010B1 (ko) 2009-09-18 2011-05-23 삼성전기주식회사 카메라 모듈
PT2554183T (pt) 2009-11-13 2018-07-09 Sanofi Aventis Deutschland Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101330868B1 (ko) 2010-06-08 2013-11-18 한미사이언스 주식회사 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체
KR101324828B1 (ko) 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
ES2953123T3 (es) 2010-06-24 2023-11-08 Boehringer Ingelheim Int Terapia para la diabetes
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
CN105142661B (zh) 2013-04-03 2019-08-16 赛诺菲 通过长效胰岛素制剂治疗糖尿病

Also Published As

Publication number Publication date
JP2014516984A (ja) 2014-07-17
RU2606840C2 (ru) 2017-01-10
BR112013030977A2 (pt) 2016-11-29
TW201305196A (zh) 2013-02-01
MY187652A (en) 2021-10-07
RU2013152335A (ru) 2015-07-20
IL229726A (en) 2017-11-30
ES2974001T3 (es) 2024-06-25
JP2017078078A (ja) 2017-04-27
US20190083579A1 (en) 2019-03-21
KR101424550B1 (ko) 2014-07-31
TWI560198B (en) 2016-12-01
US20140120120A1 (en) 2014-05-01
NZ618793A (en) 2016-01-29
WO2012165915A3 (en) 2013-03-28
EP2717918C0 (en) 2024-02-07
WO2012165915A2 (en) 2012-12-06
SG195193A1 (en) 2013-12-30
PE20140795A1 (es) 2014-06-23
US10251957B2 (en) 2019-04-09
IL229726A0 (en) 2014-01-30
EP2717918B1 (en) 2024-02-07
EP2717918A4 (en) 2015-03-18
CN109999180A (zh) 2019-07-12
AU2012263098A1 (en) 2014-01-09
CN103596595A (zh) 2014-02-19
KR20120135123A (ko) 2012-12-12
UA113626C2 (xx) 2017-02-27
CL2013003454A1 (es) 2014-06-13
CA2837856A1 (en) 2012-12-06
ZA201308811B (en) 2014-08-27
AR086660A1 (es) 2014-01-15
MX2018006844A (es) 2023-02-23
EP2717918A2 (en) 2014-04-16
PE20181079A1 (es) 2018-07-05
MX2013014029A (es) 2014-04-16
BR112013031033A2 (pt) 2016-11-29
AU2017204344A1 (en) 2017-07-13
AU2012263098B2 (en) 2017-07-20
JP6320293B2 (ja) 2018-05-09
CA2837856C (en) 2020-10-06

Similar Documents

Publication Publication Date Title
SG195193A1 (en) Composition for treating diabetes comprising long-acting insulin conjugateand long-acting insulinotropic peptide conjugate
PH12016502390A1 (en) Composition for treating diabetes mellitus comprising insulin and a glp-1/glucagon dual agonist
PH12016502391A1 (en) Composition for treating diabetes, comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate
GB2491327A (en) Delayed prolonged drug delivery
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
MX341427B (es) Un conjugado de insulina que usa un fragmento de inmunoglobulina.
NZ625391A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
NZ612187A (en) Multi-api loading prodrugs
IN2012DN02826A (es)
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
MX2013002244A (es) Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
EA201290517A1 (ru) Гетероароматические арилтриазольные производные в качестве ингибиторов фермента pde10a
IN2014MN00933A (es)
MX2013007492A (es) Dispositivo para inyectar dosis ajustables de farmaco liquido.
WO2012079093A3 (en) Dosage and administration of bispecific scfv conjugates
MX345032B (es) Antagonistas del receptor ep4 para el tratamiento de cáncer.
PH12015500653B1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
MX2014001823A (es) Combinaciones de corroles y estatinas.
MX355388B (es) Composiciones farmaceuticas y metodos terapeuticos que emplean una combinacion de un compuesto complejo de manganeso y una forma compleja no de manganeso del compuesto.
SG195192A1 (en) Non-peptidyl polymer-insulin multimer and method for producing the same
WO2011050263A3 (en) Systemic immunosuppression in the treatment of age related macular degeneration and diabetic retinopathy
Yan Vertigo Drug Shows Promise as Depression Treatment
TH154775A (th) องค์ประกอบสำหรับการรักษาโรคเบาหวานประกอบด้วยคู่อินซูลินมีฤทธิ์ระยะเวลายาวและคู่เพปไทด์อินซูลิโนโทรปิกมีฤทธิ์ระยะยาว
UA59989U (ru) Способ лечения больных стеатозом печени

Legal Events

Date Code Title Description
FG Grant or registration